BioCentury | May 18, 2017
Product R&D

Making cells compute

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...
BioCentury | Oct 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Sleep apnea In vitro , rat and pig studies identified a phenoxyaminoindane-based SLC9A3 inhibitor that could help treat sleep apnea. Screening of a small molecule library in a cell-based assay, followed by chemical synthesis and...
BioCentury | Apr 4, 2016
Product Development

Portola's mitigating factors

An underpowered cohort appears to be the culprit behind the Phase III miss for betrixaban, but Portola Pharmaceuticals Inc. plans to pursue an NDA submission for the oral Factor Xa inhibitor based on the totality...
BioCentury | Nov 10, 2014
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

Sanofi (formerly sanofi-aventis Group) disclosed in its 3Q14 earnings that it and Alopexx agreed to terminate a 2009 deal under which Sanofi gained exclusive, worldwide rights to SAR279356 , which is being developed to treat serious...
BioCentury | Nov 18, 2013
Company News

Pfizer, Sanofi pulmonary, autoimmune news

The U.S. Court of Appeals for the Federal Circuit ruled that a patent covering cDNA should be awarded to the party "who first had in hand the actual isolated DNA," regardless of whether the party...
BioCentury | Oct 7, 2013
Company News

Sanofi, National Alliance for Life Sciences and Healthcare (AVIESAN) deal

The partners extended by three years a 2010 research collaboration to develop treatments for unmet medical needs, including rare diseases. The partners said special emphasis will be placed on translational research projects. Projects under discussion...
BioCentury | Jul 15, 2013
Company News

Sanofi pharmaceuticals news

Sanofi said that its Sanofi-Aventis R&D France project, which employs more than 5,000 positions, could lead to a net reduction of 207 positions. The pharma also confirmed that it will refocus R&D in the sites...
BioCentury | May 2, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fibroblast growth factor receptor (FGFR) Two separate studies identified an allosteric inhibitor of FGFR that could help treat cancer. In...
BioCentury | May 2, 2013
Targets & Mechanisms

FGFR allosteric inhibition

Sanofi and collaborators at the Flanders Institute for Biotechnology at Catholic University Leuven have serendipitously discovered an allosteric inhibitor of the cancer target fibroblast growth factor receptor . The team hopes the allosteric mechanism will lead...
BioCentury | Dec 24, 2012
Company News

Sanofi neurology, other news

Sanofi's Sanofi U.S. Services Inc. and sanofi-aventis U.S. LLC companies will pay $109 million to the U.S. Attorney's Office, District of Massachusetts, the U.S. Department of Justice and multiple states to resolve a 2010 False...
Items per page:
1 - 10 of 2860
BioCentury | May 18, 2017
Product R&D

Making cells compute

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...
BioCentury | Oct 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Sleep apnea In vitro , rat and pig studies identified a phenoxyaminoindane-based SLC9A3 inhibitor that could help treat sleep apnea. Screening of a small molecule library in a cell-based assay, followed by chemical synthesis and...
BioCentury | Apr 4, 2016
Product Development

Portola's mitigating factors

An underpowered cohort appears to be the culprit behind the Phase III miss for betrixaban, but Portola Pharmaceuticals Inc. plans to pursue an NDA submission for the oral Factor Xa inhibitor based on the totality...
BioCentury | Nov 10, 2014
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

Sanofi (formerly sanofi-aventis Group) disclosed in its 3Q14 earnings that it and Alopexx agreed to terminate a 2009 deal under which Sanofi gained exclusive, worldwide rights to SAR279356 , which is being developed to treat serious...
BioCentury | Nov 18, 2013
Company News

Pfizer, Sanofi pulmonary, autoimmune news

The U.S. Court of Appeals for the Federal Circuit ruled that a patent covering cDNA should be awarded to the party "who first had in hand the actual isolated DNA," regardless of whether the party...
BioCentury | Oct 7, 2013
Company News

Sanofi, National Alliance for Life Sciences and Healthcare (AVIESAN) deal

The partners extended by three years a 2010 research collaboration to develop treatments for unmet medical needs, including rare diseases. The partners said special emphasis will be placed on translational research projects. Projects under discussion...
BioCentury | Jul 15, 2013
Company News

Sanofi pharmaceuticals news

Sanofi said that its Sanofi-Aventis R&D France project, which employs more than 5,000 positions, could lead to a net reduction of 207 positions. The pharma also confirmed that it will refocus R&D in the sites...
BioCentury | May 2, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fibroblast growth factor receptor (FGFR) Two separate studies identified an allosteric inhibitor of FGFR that could help treat cancer. In...
BioCentury | May 2, 2013
Targets & Mechanisms

FGFR allosteric inhibition

Sanofi and collaborators at the Flanders Institute for Biotechnology at Catholic University Leuven have serendipitously discovered an allosteric inhibitor of the cancer target fibroblast growth factor receptor . The team hopes the allosteric mechanism will lead...
BioCentury | Dec 24, 2012
Company News

Sanofi neurology, other news

Sanofi's Sanofi U.S. Services Inc. and sanofi-aventis U.S. LLC companies will pay $109 million to the U.S. Attorney's Office, District of Massachusetts, the U.S. Department of Justice and multiple states to resolve a 2010 False...
Items per page:
1 - 10 of 2860